Free Trial
NASDAQ:PRLD

Prelude Therapeutics (PRLD) Stock Price, News & Analysis

Prelude Therapeutics logo
$0.65 -0.03 (-3.99%)
Closing price 04/7/2025 04:00 PM Eastern
Extended Trading
$0.66 +0.01 (+1.84%)
As of 04/7/2025 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Prelude Therapeutics Stock (NASDAQ:PRLD)

Key Stats

Today's Range
$0.61
$0.72
50-Day Range
$0.64
$1.19
52-Week Range
$0.61
$6.80
Volume
281,323 shs
Average Volume
261,532 shs
Market Capitalization
$35.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Hold

Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Remove Ads

Prelude Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

PRLD MarketRank™: 

Prelude Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 526th out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Prelude Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Prelude Therapeutics has received no research coverage in the past 90 days.

  • Read more about Prelude Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Prelude Therapeutics are expected to remain at ($1.81) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Prelude Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Prelude Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Prelude Therapeutics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Prelude Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.35% of the float of Prelude Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Prelude Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Prelude Therapeutics has recently increased by 4.17%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Prelude Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Prelude Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.35% of the float of Prelude Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Prelude Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Prelude Therapeutics has recently increased by 4.17%, indicating that investor sentiment is decreasing.
    • Insider Buying vs. Insider Selling

      In the past three months, Prelude Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $568,475.00 in company stock and sold $0.00 in company stock.

    • Percentage Held by Insiders

      62.80% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Prelude Therapeutics' insider trading history.
    Receive PRLD Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    PRLD Stock News Headlines

    Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
    Musk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.
    Prelude Therapeutics Founder Acquires 28% More Stock
    Prelude Therapeutics CEO buys $467K in common stock
    See More Headlines

    PRLD Stock Analysis - Frequently Asked Questions

    Prelude Therapeutics' stock was trading at $1.2750 at the beginning of 2025. Since then, PRLD shares have decreased by 49.2% and is now trading at $0.6481.
    View the best growth stocks for 2025 here
    .

    Prelude Therapeutics Incorporated (NASDAQ:PRLD) issued its earnings results on Monday, March, 10th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.11. The firm had revenue of $4 million for the quarter.

    Prelude Therapeutics (PRLD) raised $149 million in an IPO on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO.

    Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD).

    Company Calendar

    Last Earnings
    3/10/2025
    Today
    4/07/2025
    Next Earnings (Estimated)
    5/06/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:PRLD
    Fax
    N/A
    Employees
    120
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $4.00
    High Stock Price Target
    $5.00
    Low Stock Price Target
    $3.00
    Potential Upside/Downside
    +517.2%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.33
    Research Coverage
    3 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-121,830,000.00
    Pretax Margin
    -4,383.90%

    Debt

    Sales & Book Value

    Annual Sales
    $7 million
    Price / Cash Flow
    N/A
    Book Value
    $4.32 per share
    Price / Book
    0.15

    Miscellaneous

    Free Float
    20,473,000
    Market Cap
    $35.75 million
    Optionable
    Optionable
    Beta
    1.35
    Ten Starter Stocks For Beginners to Buy Now Cover

    Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

    Get This Free Report

    This page (NASDAQ:PRLD) was last updated on 4/8/2025 by MarketBeat.com Staff
    From Our Partners